Having trouble accessing articles? Reset your cache.

Breaking through the BBB

The idea of using the brain's own transport receptors to ferry drugs across the blood-brain barrier has been around for more than a decade. AngioChem Inc., one of a new generation of companies trying to take advantage of natural transport molecules in the brain, is the first to report proof-of-concept data on delivering therapeutics across the divide in humans.

The next step will be to find a partner.

AngioChem's delivery technology uses peptides derived from endogenous ligands of the low-density lipoprotein receptor-related protein (LRP) receptor,

Read the full 838 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers